

PHARMACY AND POISONS BOARD
HONG KONG
香港藥劑業及毒藥管理局

Your Ref. :
貴處檔號

Our Ref. : DH DO PRIE/1-55/1
本局檔號

Tel. No. : 2319 8468
電 話

Fax No. : 2803 4962
圖文傳真

C/O Drug Office
3/F., Public Health Laboratory Centre,
382 Nam Cheong Street,
Kowloon, Hong Kong.
香港九龍南昌街382號
公共衛生檢測中心三樓

9th September 2016

To: Certificate holders of
registered pharmaceutical products

Dear Sirs / Madams,

New Safety Warnings for Olanzapine

On 7th September 2016, the Pharmacy and Poisons (Registration of Pharmaceutical Products and Substances: Certification of Clinical Trial/Medicinal Test) Committee (the Committee) considered the latest overseas recommendations on the risk of drug reaction with eosinophilia and systemic symptoms (DRESS) associated with the use of olanzapine, and decided that the sales pack labels and/or package inserts of registered pharmaceutical products containing olanzapine should include the following new safety warnings:

Precautions

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported with olanzapine exposure. DRESS consists of a combination of three or more of the following: cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, lymphadenopathy and one or more systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and pericarditis. Discontinue olanzapine if DRESS is suspected.

You are therefore required to review and revise, if necessary, the sales pack labels and/or package inserts of the concerned products registered by your company to ensure that the products comply with the above requirements. The revised sales pack labels and/or package inserts should be submitted to the Committee for approval within 2 months from the date of this letter. Failing to comply with the above requirements may result in de-registration of the products by the Committee.

If you have any enquiries on the above issue, please contact Ms Sheila Chung at 2319 8449.

Yours sincerely,



(Clive CHAN)

Secretary,

Pharmacy and Poisons (Registration of
Pharmaceutical Products and Substances: Certification
of Clinical Trial/Medicinal Test) Committee

c.c. 7-15/3, Product Files

SM/CC